Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | AXL | P30530 | 6/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 6/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.48 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436248 | 0.89 | KDR (0.54) | KDRAXLNTRK1KCNK3KCNK9 | |
| SCHEMBL5440253 | 0.87 | AXL (0.54) | KDRAXLCSF1RPDGFRBPDGFRA | |
| SCHEMBL5443568 | 0.86 | KDR (0.58) | KDRAXLNTRK1CSF1RPDGFRB | |
| SCHEMBL5443642 | 0.86 | AXL (0.51) | KDRAXLCSF1RPDGFRBPDGFRA | |
| SCHEMBL5443654 | 0.86 | AXL (0.51) | KDRAXLNTRK1CSF1RPDGFRB | |
| SCHEMBL5441873 | 0.85 | NTRK1 (0.61) | KDRAXLNTRK1CSF1RPDGFRB | |
| SCHEMBL5338565 | 0.85 | KDR (0.71) | KDRAXLCSF1R | |
| SCHEMBL5335714 | 0.84 | AXL (0.50) | KDRAXLNTRK1CSF1RPDGFRB | |
| SCHEMBL27864410 | 0.84 | KDR (0.72) | KDRNTRK1CSF1RPDGFRBPDGFRA | |
| SCHEMBL28793967 | 0.84 | KDR (0.72) | KDRNTRK1CSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 508/4885AXL 7/4885NTRK1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.